Equine Encephalitis - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Equine Encephalitis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Equine Encephalitis - Pipeline Review, H2 2015', provides an overview of the Equine Encephalitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Equine Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Equine Encephalitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Equine Encephalitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Equine Encephalitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Equine Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Equine Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Equine Encephalitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Equine Encephalitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Equine Encephalitis Overview 7
Therapeutics Development 8
Pipeline Products for Equine Encephalitis - Overview 8
Pipeline Products for Equine Encephalitis - Comparative Analysis 9
Equine Encephalitis - Therapeutics under Development by Companies 10
Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes 11
Equine Encephalitis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Equine Encephalitis - Products under Development by Companies 14
Equine Encephalitis - Products under Investigation by Universities/Institutes 15
Equine Encephalitis - Companies Involved in Therapeutics Development 16
Akshaya Bio Inc. 16
AltraVax Inc. 17
EpiVax, Inc. 18
Karyopharm Therapeutics, Inc. 19
Profectus BioSciences, Inc. 20
PsiOxus Therapeutics Limited 21
Equine Encephalitis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
DEF-201 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
equine encephalitis vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
equine encephalitis vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
equine encephalitis vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
imatinib mesylate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
nilotinib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TSI-GSD-104 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Vaccine for Western Equine Encephalitis - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VEEC-84 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
venezuelan equine encephalitis vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
venezuelan equine encephalitis vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Venezuelan equine encephalitis vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
verdinexor - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Westrern Equine Encephalitis Virus Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Equine Encephalitis - Recent Pipeline Updates 47
Equine Encephalitis - Dormant Projects 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Number of Products under Development for Equine Encephalitis, H2 2015 8
Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Equine Encephalitis - Pipeline by Akshaya Bio Inc., H2 2015 16
Equine Encephalitis - Pipeline by AltraVax Inc., H2 2015 17
Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2015 18
Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 19
Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2015 20
Equine Encephalitis - Pipeline by PsiOxus Therapeutics Limited, H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Stage and Target, H2 2015 24
Number of Products by Stage and Mechanism of Action, H2 2015 26
Number of Products by Stage and Route of Administration, H2 2015 28
Number of Products by Stage and Molecule Type, H2 2015 30
Equine Encephalitis Therapeutics - Recent Pipeline Updates, H2 2015 47
Equine Encephalitis - Dormant Projects, H2 2015 48